Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: A single-blinded pilot study
Topical tacrolimus has demonstrated efficacy in vitiligo. This study compared the efficacy and safety of 0.1% tacrolimus ointment with 0.1% mometasone furoate cream in adult vitiligo. We enrolled patients with symmetrical, nonacral vitiligo, and the patients on each side were randomized to receive e...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Wolters Kluwer Medknow Publications,
2016-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Topical tacrolimus has demonstrated efficacy in vitiligo. This study compared the efficacy and safety of 0.1% tacrolimus ointment with 0.1% mometasone furoate cream in adult vitiligo. We enrolled patients with symmetrical, nonacral vitiligo, and the patients on each side were randomized to receive either 0.1% tacrolimus ointment or 0.1% mometasone furoate cream, applied twice daily for 6 months. Repigmentation outcome at 6 months was compared with baseline. Of 18 cases, 22% and 33% in tacrolimus and mometasone groups, respectively, displayed more than 50% repigmentation (p > 0.05). Telangiectasia was presented in one-third of cases on the mometasone-treated side. Both treatments were effective in vitiligo; however, 0.1% tacrolimus ointment has fewer adverse effects. |
|---|---|
| Item Description: | 1027-8117 10.1016/j.dsi.2016.05.005 |